Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HB0025 plus nab-paclitaxel for first-line TNBC
NCT07376629Phase 2Enrolling by invitation
- Sponsor
- Huabo Biopharm
- Start
- Aug 2025
- Primary completion
- Jan 2027
- Countries
- 1
01
Overview
A Phase 2 trial of sotiburafusp alfa in triple-negative breast cancer (TNBC), sponsored by Huabo Biopharm. Started Aug 2025; status: enrolling by invitation.
02
Drugs
sotiburafusp alfa
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07376629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07376629.